Hepatoma/merbarone. A Southwest Oncology Group study.
Invest New Drugs
; 12(4): 337-40, 1994.
Article
in En
| MEDLINE
| ID: mdl-7775137
ABSTRACT
Sixteen eligible patients with hepatocellular carcinoma, previously untreated, received merbarone 1000 mg/m2/d for five consecutive days every 21 days. No complete or partial response to treatment was obtained. Seven patients had grade 4 granulocytopenia. One patient died with renal failure. Merbarone in this dose and schedule was ineffective in the treatment of hepatocellular carcinoma.
Search on Google
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Thiobarbiturates
/
Carcinoma, Hepatocellular
/
Liver Neoplasms
/
Antineoplastic Agents
Limits:
Adult
/
Aged
/
Female
/
Humans
/
Male
/
Middle aged
Language:
En
Journal:
Invest New Drugs
Year:
1994
Document type:
Article
Affiliation country:
Estados Unidos